Bioxytran (BIXT) Share-based Compensation (QoQ) (2010 - 2026)
Bioxytran (BIXT) Share-based Compensation (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.69% |
| Dec 31, 2025 | -2.81% |
| Sep 30, 2025 | 230.89% |
| Jun 30, 2025 | -154.80% |
| Mar 31, 2025 | 534.29% |
| Dec 31, 2024 | 71.03% |
| Sep 30, 2024 | -21.28% |
| Jun 30, 2024 | -98.60% |
| Mar 31, 2024 | -74.67% |
| Dec 31, 2023 | 3,610.88% |
| Sep 30, 2023 | 22,488.33% |
| Jun 30, 2023 | -57.65% |
| Mar 31, 2023 | 132.10% |
| Dec 31, 2022 | -103.60% |
| Sep 30, 2022 | 57.33% |
| Jun 30, 2022 | 108.58% |
| Mar 31, 2022 | 105.54% |
| Dec 31, 2021 | -47,967.54% |
| Sep 30, 2021 | -98.35% |
| Jun 30, 2021 | -93.41% |